Evidence map›Paper›PMID 41099968›Full record

ArticleJournal of neuro-oncology2025

Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.

Pushan Dasgupta, Samir A Dagher, Xiaohan Chi, Zaid Soomro, Surya Bhat, Erick Campbell, Max Wintermark, Vinay K Puduvalli, Ruitao Lin, Melissa M Chen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pushan Dasgupta *Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pushan.dasgupta@bcm.edu.
Samir A Dagher *Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Xiaohan ChiDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zaid SoomroDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Surya BhatDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erick CampbellDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Max WintermarkDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vinay K PuduvalliDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa M ChenDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mchen9@mdanderson.org.
Nazanin K MajdDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. nkmajd@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGliomatosis cerebri (GC) is defined as a diffusely infiltrative pattern of growth affecting at least three contiguous lobes of the brain. GC presents unique challenges in terms of surgery and radiation therapy. We evaluated the genomic determinants of GC.

methodsIn this retrospective study, we evaluated genetic alterations and overall (OS) and progression-free survival (PFS) durations in radiographically verified cases of GC (glioblastoma [GBM]-GC or astrocytoma IDH mutant-GC) from 2013 to 2023 and their matched non-GC controls.

resultsWe identified 63 GC cases (45 GBM-GC and 18 astrocytoma IDH mutant-GC) and 126 matched controls. Statistically significant alterations in telomerase reverse transcriptase (TERT) promoter were found in 68% of the GBM matched controls versus only 38% of the GBM-GC patients (p = 0.002 and false discovery rate (FDR) = 0.04). The same held true for the subgroup of primary GBM-GC (p = 0.002 and FDR = 0.04) but not for secondary GBM-GC. In terms of PFS duration, the GBM-GC patients did not significantly differ from the matched controls (p = 0.720). However, the astrocytoma IDH mutant-GC patients had a shorter PFS duration than did the matched controls (p = 0.036). In terms of OS duration, neither the GBM-GC group nor the astrocytoma, IDH mutant-GC group significantly differed (p = 0.589 and p = 0.39, respectively). None of the genetic alterations in these groups were significantly associated with PFS or OS duration.

conclusionsThe lower frequency of TERT promoter mutations in GBM-GC may be a characteristic of primary GBM-GC. GC patients had similar OS durations to those of matched non-GC controls. Further studies are needed to validate these results, given this study’s small sample size and retrospective nature. This study supports further efforts to understand the molecular characteristics of GC and perhaps include patients with GC in more clinical trials.

Indexed as

Biomarkers, TumorBrain NeoplasmsMutationNeoplasms, NeuroepithelialAdultAgedFemaleFollow-Up StudiesGenomicsHumansIsocitrate DehydrogenaseMaleMiddle AgedPhenotypePrognosisPromoter Regions, GeneticBiomarkers, TumorIsocitrate DehydrogenaseTelomeraseTERT protein, humanAstrocytomaDiffusely infiltrative gliomaGlioblastomaGliomatosis cerebriHigh-grade gliomaMultifocal glioma

Identifiers

PMID41099968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.